Promore Pharma
9.11.2021 12:02:15 CET | ACCESS Newswire | Press release
STOCKHOLM, SE / ACCESSWIRE / November 9, 2021 / Promore Pharma (STO:PROMO)(FRA:8T0)
Stockholm, November 9, 2021 - Promore Pharma AB, a Swedish biopharmaceutical company that develops peptide-based drug candidates, announced today that the company has received approval from the Medical Products Agency and the Swedish Ethics Review Authority to begin a clinical phase II trial of ensereptide for skin scarring prevention.
The company announces today that a clinical trial permit has been obtained from the Medical Products Agency in Sweden and that the company's application for approval from the Ethical Review Authority has also been granted. PHSU05 is a Phase II pilot study with the aim of being able to evaluate ensereptide regarding (i) local tolerance, (ii) the application process of the experimental drug, and (iii) preliminary effect on scar prevention after experimentally induced wounds in healthy volunteers. Planned study start is Q1 2022 and results from the study are expected in the winter of 2022/2023.
"This is an important step in our long-term goal of developing a new product concept to prevent the occurrence of post-surgical and post-traumatic scars on the skin. These approvals are fully aligned with our operational plan in the ensereptide project ", says Jonas Ekblom, CEO of Promore Pharma.
Bolagets ensereptide-program fokuseras för närvarande på prevention av ärr i huden i samband med kirurgi eller trauma, men det finns även potential att utveckla produkten för andra medicinska applikationer som prevention av sammanväxning efter hand- och ryggradskirurgi.
The company's ensereptide program is currently focused on the prevention of scarring of the skin in connection with surgery or trauma, but there is also potential to develop the product for other medical applications such as prevention of adhesions after surgeries in the hand or spine.
Scars develop after virtually all types of damage to the skin. Although scars can often be considered trivial, a large proportion of them can be disfiguring and aesthetically pleasing, and they can also create itching, stiffness, sleep problems, anxiety, depression and negatively affect activities of daily life.
The world market for products for the treatment of scars, including laser treatment, scar revision and self-care products, amounts to USD 25 billion with an annual growth of about 10%, according to independent estimates. Today, there are no prescription drugs for wound prevention.
For additional information, please contact
Jonas Ekblom, CEO
Phone: [+46] 736 777 540
E-mail: jonas.ekblom@promorepharma.com
Erik Magnusson, CFO
Phone: [+46] 708 565 245
E-mail: erik.magnusson@promorepharma.com
Promore Pharmas Certified Adviser is Erik Penser Bank
Tel: [+46] 8-463 83 00
E-mail: certifiedadviser@penser.se
Promore Pharma in brief
Promore Pharma is a biopharmaceutical company specialized in the development of therapeutic peptides. The company's aim is to develop first-in-category pharmaceuticals for indications with high unmet medical needs, where very few efficacious prescription pharmaceuticals are available. Promore Pharma's two projects are undergoing clinical development and have a very strong safety profile since the products are based on endogeneous substances that are administered locally. The leading project, ensereptide (PXL01), that will be used for prevention of post-surgical scarring, is being prepared for a clinical phase II-trial if the peptide can prevent the formation of unesthetical scars on the skin. Ropocamptide (LL-37) has recently been evaluated in a clinical phase IIb study with positive results in patients with venous leg ulcers (VLUs). The product candidates can also be deployed for other indications, such as preventing unfavorable tissue attachments (adhesions) after different kinds of surgical procedures and treatment of diabetic foot ulcers. The company is listed on Nasdaq First North Growth Market.
This information is information that Promore Pharma is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2021-11-09 11:38 CET.
Attachments
Promore Pharma receives permits to start a phase II clinical trial regarding scar prevention
SOURCE: Promore Pharma
View source version on accesswire.com:
https://www.accesswire.com/671849/Promore-Pharma-Receives-Permits-to-Start-a-Phase-II-Clinical-Trial-Regarding-Scar-Prevention
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
LiberNovo Previews Treat Yourself Halloween Flash Sale Across Europe29.10.2026 08:40:00 CET | Press release
HONG KONG, HK / ACCESS Newswire / October 29, 2026 / LiberNovo is bringing Halloween treats to the desk with its Treat Yourself Halloween Flash Sale, opening October 29 across the European Union and United Kingdom. The event pairs savings of up to 40% on selected Maxis and LiberNovo Omni Pro configurations with limited seasonal gifts for qualifying early shoppers. Spooky extras for your desk Limited Halloween-themed gift packs are available to the first 300 eligible customers in the European Union and the first 100 in the United Kingdom, on a first-come, first-served basis while supplies last. Gift contents, qualifying purchases and availability follow the terms on each regional campaign page. More room for Big and Tall users Maxis is designed around larger frames, with a wider seat and 52 cm seat depth for greater thigh support and room to shift naturally. Maxis Manual provides adjustment by hand. Maxis Electric adds motorised lumbar adjustment and OmniStretch guided back stretching.
IAVI Awarded $36 Million From BARDA for Bundibugyo Virus Vaccine Development28.10.2026 16:50:00 CET | Press release
NEW YORK, NY, SINGAPORE, SG INCHEON, SOUTH KOREA, AND DESSAU-ROSSLAU, DE / ACCESS Newswire / October 28, 2026 / Today IAVI, a global nonprofit biomedical research organization, together with partners Hilleman Laboratories, SK bioscience, and IDT Biologika announced that IAVI has been awarded US $36 million of a contract valued up to US $99 million from the Administration for Strategic Preparedness and Response (ASPR); Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services, to advance development, manufacturing, and clinical evaluation of its one-dose vaccine candidate against Bundibugyo virus (BDBV), the cause of the ongoing Ebola epidemic in the Democratic Republic of the Congo (DRC). The award supports manufacturing of vaccine doses for clinical evaluation and outbreak response, clinical and regulatory activities including a Phase 1 trial, and options for expanded manufacturing to support future preparedness needs, as
GA-ASI and Saab Perform Advanced AEW Flight Testing on Uncrewed MQ-9B28.10.2026 16:00:00 CET | Press release
SAN DIEGO, CA / ACCESS Newswire / October 28, 2026 / General Atomics Aeronautical Systems, Inc. (GA-ASI) has partnered with Saab to perform advanced flight testing of an Airborne Early Warning (AEW) system on an Uncrewed Aircraft System (UAS). The flight testing was conducted over the past few months using a GA-ASI-produced MQ-9B carrying a Saab LoyalEye radar operating from GA-ASI's Desert Horizon flight operations facility in Southern California. The flight test demonstrated simultaneous tracking of several airborne and maritime targets at long ranges. The airborne targets tracked included multiple instrumented red fighter jets and several commercial aircraft. MQ-9B is GA-ASI's flagship UAS, offering unmatched endurance, type certification and all-weather performance. GA-ASI is discussing unmanned AEW capabilities on MQ-9B with several customers. "This has been one of the most highly anticipated flight tests we have performed," said GA-ASI President David R. Alexander. "The level of
Juno Corp. Closes $25 Million Non-Brokered Private Placement28.10.2026 12:00:00 CET | Press release
TORONTO, ON / ACCESS Newswire / October 28, 2026 / Juno Corp. ("Juno" or the "Company"), the largest mineral claim holder and most active explorer in Ontario's Ring of Fire, is pleased to announce that it has completed a non-brokered private placement (the "Offering") for aggregate gross proceeds of $25,290,609. Pursuant to the Offering, the Company issued an aggregate of (i) 165,750 common shares of Juno ("HD Juno Shares"), on a non-flow-through basis at a price of $4.00 per HD Juno Share, (ii) 404,890 common shares of Juno that qualify as "flow-through shares" as defined in subsection 66(15) of the Income Tax Act (Canada) (the "Tax Act") (the "FT Juno Shares"), at a price of $4.50 per FT Juno Share, and (iii) 4,131,450 common shares of Juno, which qualify as "flow-through shares" as defined in subsection 66(15) of the Tax Act (the "Premium FT Juno Shares", and together with the HD Juno Shares and the FT Juno Shares, the "Juno Securities"), at a price of $5.52 per Premium FT Juno Shar
DistillerSR Launches Smart Chat, an AI Chat Interface Built Into Its Evidence Platform27.10.2026 15:55:00 CET | Press release
OTTAWA, ON / ACCESS Newswire / October 27, 2026 / DistillerSR® Inc., the pioneer and market leader in AI-enabled literature review automation and evidence management, today announced the launch of Smart Chat. Smart Chat brings DistillerSR's Agentic AI capabilities in-platform. Since September 2025, DistillerSR Agentic AI has eliminated evidence silos at customer organizations by connecting Large Language Models to a repository of expertly validated literature evidence. Smart Chat now makes that same capability available natively within DistillerSR's secure platform. "While researchers recognize the power of generative AI, many life sciences organizations cannot risk connecting external LLMs to their sensitive research data," said Peter O'Blenis, CEO of DistillerSR. "Smart Chat removes that barrier. It is built directly into the platform teams already use, works exclusively with their own DistillerSR projects, and is included with every version of DistillerSR." Smart Chat works only wit
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom